Question 1

What did AMPLITUDE-O actually find?

Accepted Answer

On its primary endpoint — A nonfatal heart attack, a nonfatal stroke, or death from cardiac or undetermined causes — whichever came first — the treatment arm recorded 189 of 2,717 (7.0%); 3.9 events per 100 person-years against 125 of 1,359 (9.2%); 5.3 events per 100 person-years for the comparator. Hazard ratio 0.73 (95% CI 0.58 to 0.92); P<0.001 for noninferiority; P=0.007 for superiority. ★ A 27% reduction, among the larger effects in this class, and achieved in the shortest follow-up of any positive trial here. It is also the first positive cardiovascular result for a drug built on the lizard-derived peptide rather than a copy of the human hormone — which matters for the class-effect argument below.

Question 2

How large was AMPLITUDE-O, and how long did it run?

Accepted Answer

4,076 participants, over A median 1.81 years — the trial ran until enough events had accumulated rather than to a fixed date. It was a Phase 3 trial, ran to completion in December 2020 and published in September 2021 with its endpoint met — then the registry entry was marked terminated, because Sanofi ended the development program. The drug was never filed for approval in the US or Europe.. Registered as NCT03496298, which you can look up yourself rather than taking anyone's summary for it.

Question 3

Who was studied in AMPLITUDE-O?

Accepted Answer

Adults with type 2 diabetes entering by one of two routes: a history of cardiovascular disease, or kidney disease with filtration between 25 and 59.9 plus at least one cardiovascular risk factor. ⚠ 89.6% arrived with established cardiovascular disease, the highest proportion of any trial in this class — which is why it reached its event target so fast. Average age 64.5, 33% women, average HbA1c 8.9%, average BMI 32.7, and over 15 years since diagnosis. ★ 15.2% were already on an SGLT2 inhibitor, more than any earlier trial in this class, and randomization was balanced for it. ⚠ A trial result describes the population it was measured in. If you differ from it materially — in age, in baseline weight, in whether you have diabetes — the number is context rather than a prediction.

Question 4

What side effects were reported in AMPLITUDE-O?

Accepted Answer

The most commonly reported were stomach and bowel problems as a group (Higher with efpeglenatide than placebo (category-level finding reported in the NEJM abstract; arm-specific percentages reported in the full text are behind the NEJM paywall and not reproduced here) against Lower than the efpeglenatide arms on comparator), pancreatitis, confirmed by independent review (No imbalance versus placebo reported in the NEJM publication against Reference on comparator), pancreatic cancer (No imbalance versus placebo reported in the NEJM publication against Reference on comparator). ⚠ These were the dominant tolerability problem, more common on the drug than placebo, matching every other drug in this class. The publication reports them as a category rather than breaking each one out by arm, so we cannot give you per-symptom rates here — the primary paper is the place to look if you need them. Rates come from this trial's population under its own dose-escalation schedule; a faster or slower titration changes what people experience.

Question 5

What else did AMPLITUDE-O measure?

Accepted Answer

Secondary endpoints included the same count, at the higher dose only (84 of 1,358 (6.2%) on efpeglenatide 6 mg against 125 of 1,359 (9.2%) on placebo); the same count, at the lower dose only (105 of 1,359 (7.7%) on efpeglenatide 4 mg against 125 of 1,359 (9.2%) on placebo); kidney decline: sustained new protein in the urine, a 40% drop in filtration, or kidney failure (353 of 2,717 (13.0%) against 250 of 1,359 (18.4%)). ⚠ Secondary endpoints are weaker evidence than the primary one — a trial is powered for its primary outcome, and the rest are read as supporting rather than as findings in their own right.

Question 6

Does AMPLITUDE-O mean this drug will work for me?

Accepted Answer

It cannot tell you that. A trial reports an average across a defined population under a fixed protocol, with monitoring and adherence support most people do not get. It is the best evidence available and it is still a distribution rather than a promise — some participants lost far more than the mean and some lost nothing. What it is genuinely good for is comparing options against each other, which is what the rest of this section is for.

Endpoint	Treatment	Comparator	Difference
The same count, at the higher dose only ★ A 35% reduction — the larger of the two doses and what carried the headline.	84 of 1,358 (6.2%) on efpeglenatide 6 mg	125 of 1,359 (9.2%) on placebo	Hazard ratio 0.65 (95% CI 0.50 to 0.86); P=0.0027
The same count, at the lower dose only An 18% reduction that did not reach significance on its own. ★ Read the two doses together and the ordering is the point: placebo, then 4 mg, then 6 mg, consistently across every outcome.	105 of 1,359 (7.7%) on efpeglenatide 4 mg	125 of 1,359 (9.2%) on placebo	Hazard ratio 0.82 (95% CI 0.63 to 1.06); P=0.14
Kidney decline: sustained new protein in the urine, a 40% drop in filtration, or kidney failure ★ Down 32% — one of the largest kidney signals ever reported in a trial not built to measure kidneys, and part of what made a dedicated kidney trial in this class worth funding.	353 of 2,717 (13.0%)	250 of 1,359 (18.4%)	Hazard ratio 0.68 (95% CI 0.57 to 0.79); P<0.001
The same kidney count, at the higher dose 37% fewer. The dose response was steeper on kidneys than on hearts.	Efpeglenatide 6 mg arm	Placebo arm	Hazard ratio 0.63 (95% CI not reported in abstract); P<0.0001
The same kidney count, at the lower dose ★ 27% fewer, and formally significant — the only outcome where the lower dose stood up on its own. If kidneys are the concern, the lower dose still did something.	Efpeglenatide 4 mg arm	Placebo arm	Hazard ratio 0.73 (95% CI not reported in abstract); P=0.0009
A wider cardiac count adding stent and bypass procedures and unstable-angina admissions, at the higher dose 27% fewer at the top dose; the lower dose showed a 15% trend that did not reach significance.	Efpeglenatide 6 mg arm	Placebo arm	Hazard ratio 0.73; P=0.011
Cardiac events or death from any cause, at the higher dose 33% fewer at the top dose, with the lower dose showing a 19% trend.	Efpeglenatide 6 mg arm	Placebo arm	Hazard ratio 0.67; P=0.0021
The harder kidney measure — a 40% loss of filtration, kidney failure, or death — at the higher dose ⚠ 39% fewer at the top dose, and completely flat at the lower one. This is the only endpoint where the two doses genuinely diverged rather than differing in degree.	Efpeglenatide 6 mg arm	Placebo arm	Hazard ratio 0.61; P=0.0072
The broadest planned count, combining cardiac events, death, heart failure and kidney decline 37% fewer at the top dose; the lower dose came in at 19% and just missed significance.	Efpeglenatide 6 mg arm	Placebo arm	Hazard ratio 0.63; P=0.0002
Whether more drug meant more benefit, across every outcome measured ★ The most useful thing this trial produced, and the reason it is still cited for a drug nobody can buy. The ordering held across every endpoint with a statistically significant trend — which is the cleanest evidence in this class that pushing to a higher dose amplifies the cardiac and kidney benefit, not just the weight and blood sugar.	Placebo < 4 mg < 6 mg ordering across endpoints	Reference (placebo)	P for trend ≤0.018 across all primary and secondary cardiovascular and kidney outcomes

Event	Treatment rate	Comparator rate
Stomach and bowel problems as a group ⚠ These were the dominant tolerability problem, more common on the drug than placebo, matching every other drug in this class. The publication reports them as a category rather than breaking each one out by arm, so we cannot give you per-symptom rates here — the primary paper is the place to look if you need them.	Higher with efpeglenatide than placebo (category-level finding reported in the NEJM abstract; arm-specific percentages reported in the full text are behind the NEJM paywall and not reproduced here)	Lower than the efpeglenatide arms
Pancreatitis, confirmed by independent review No imbalance against placebo, consistent with every large trial in this class.	No imbalance versus placebo reported in the NEJM publication	Reference
Pancreatic cancer ⚠ No imbalance reported — but at a median 1.8 years this trial is far too short for cancer risk to declare itself. Read it as no early signal, not as reassurance about long-term use.	No imbalance versus placebo reported in the NEJM publication	Reference
Diabetic eye disease getting worse ★ No eye signal, in contrast to the clear one the injectable semaglutide trial found. Both the short follow-up and the different molecular backbone may play a part, and neither explanation has been established.	No retinopathy safety signal reported in the NEJM publication	Reference
Stopped the drug over a side effect Higher than placebo, driven by stomach and bowel intolerance — the usual pattern for this class.	Higher with efpeglenatide than placebo per the NEJM publication; specific percentages in the full text and supplement	Lower than the efpeglenatide arms

AMPLITUDE-O: A Positive Trial for a Drug Nobody Can Buy

Primary endpoint

Secondary endpoints

Adverse events

Subgroup analyses

Clinical significance

Frequently Asked Questions

References

Related trial deep-dives